Merck & Co., Inc. (MRK) — Stock Price, Chart & Analysis
Merck & Co., Inc. (MRK) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $372.32B and a trailing P/E ratio of 118.83. Over the past 52 weeks, MRK has traded between $77.58 and $156.92. Merck & Co., Inc. pays a dividend yielding 2.3%. View the live MRK chart, technical opinion, analyst ratings, fundamentals and latest news below.
Merck & Co., Inc. (MRK) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $372.32B |
| P/E ratio (TTM) | 118.83 |
| EPS (TTM) | $1.27 |
| Dividend yield | 2.3% |
| 52-week high | $156.92 |
| 52-week low | $77.58 |
| Beta | 0.23 |
| Avg. volume | 10.15M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Merck & Co., Inc. (MRK)
How much does one share of Merck & Co., Inc. cost?
As of the latest update, one share of Merck & Co., Inc. (MRK) trades at $100 (+0.00% today).
What is Merck & Co., Inc.'s market cap?
Merck & Co., Inc. has a market capitalization of approximately $372.32B.
What is Merck & Co., Inc.'s P/E ratio?
Merck & Co., Inc. has a trailing price-to-earnings (P/E) ratio of 118.83.
What is Merck & Co., Inc.'s earnings per share (EPS)?
Merck & Co., Inc.'s trailing twelve-month EPS is $1.27.
Does Merck & Co., Inc. pay a dividend?
Yes — Merck & Co., Inc. pays a dividend with a yield of 2.3% ($3.40 per share annually).
What is Merck & Co., Inc.'s 52-week trading range?
Over the past year, MRK has traded between $77.58 and $156.92.
What is the analyst price target for Merck & Co., Inc.?
The mean analyst price target for Merck & Co., Inc. is $152.96. This is informational only and not investment advice.
Latest Merck & Co., Inc. (MRK) news
- Could You Have Seen Merck Stock's Pipeline Run Coming?News · Sep 22, 2026
- Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?News · Sep 22, 2026
- Why Is Merck (MRK) In Focus After Japan Cleared A New Dosing Option?News · Sep 22, 2026
- Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge HigherNews · Sep 21, 2026
- Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder CancerNews · Sep 21, 2026
- Was Moderna Stock's Cancer Vaccine Run Visible In Advance?News · Sep 22, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live MRK dashboard…